230 related articles for article (PubMed ID: 3035025)
21. A myasthenia gravis plasma immunoglobulin reduces miniature endplate potentials at human endplates in vitro.
Burges J; Wray DW; Pizzighella S; Hall Z; Vincent A
Muscle Nerve; 1990 May; 13(5):407-13. PubMed ID: 2345558
[TBL] [Abstract][Full Text] [Related]
22. Recombinant human acetylcholine receptor alpha-subunit induces chronic experimental autoimmune myasthenia gravis.
Lennon VA; Lambert EH; Leiby KR; Okarma TB; Talib S
J Immunol; 1991 Apr; 146(7):2245-8. PubMed ID: 2005394
[TBL] [Abstract][Full Text] [Related]
23. Acetylcholine release in myasthenia gravis: regulation at single end-plate level.
Plomp JJ; Van Kempen GT; De Baets MB; Graus YM; Kuks JB; Molenaar PC
Ann Neurol; 1995 May; 37(5):627-36. PubMed ID: 7755358
[TBL] [Abstract][Full Text] [Related]
24. Lewis rats given antibodies against denatured acetylcholine receptor become resistant to induction of experimental autoimmune myasthenia gravis.
Krolick KA; Yeh TM; Edlund SA
Cell Immunol; 1996 Aug; 172(1):10-20. PubMed ID: 8806801
[TBL] [Abstract][Full Text] [Related]
25. Monoclonal anti-acetylcholine receptor antibodies with differing capacities to induce experimental autoimmune myasthenia gravis.
Gomez CM; Richman DP
J Immunol; 1985 Jul; 135(1):234-41. PubMed ID: 3873489
[TBL] [Abstract][Full Text] [Related]
26. FK506 prevents induction of rat experimental autoimmune myasthenia gravis.
Yoshikawa H; Iwasa K; Satoh K; Takamori M
J Autoimmun; 1997 Feb; 10(1):11-6. PubMed ID: 9080295
[TBL] [Abstract][Full Text] [Related]
27. Specificities of antibody to acetylcholine receptor in rabbits with experimental myasthenia gravis.
Ueno S; Kang J; Takeuchi H; Takahashi M; Tarui S
Clin Exp Immunol; 1980 Jul; 41(1):13-8. PubMed ID: 6777100
[TBL] [Abstract][Full Text] [Related]
28. Congenital myasthenic syndromes: II. Syndrome attributed to abnormal interaction of acetylcholine with its receptor.
Uchitel O; Engel AG; Walls TJ; Nagel A; Atassi MZ; Bril V
Muscle Nerve; 1993 Dec; 16(12):1293-301. PubMed ID: 8232384
[TBL] [Abstract][Full Text] [Related]
29. In vitro blockade of neuromuscular transmission by monoclonal anti-acetylcholine receptor antibodies.
Maselli RA; Jow B; Richman DP; Nelson DJ
Ann N Y Acad Sci; 1988; 540():523-4. PubMed ID: 2849901
[No Abstract] [Full Text] [Related]
30. Autoantibodies in myasthenia gravis: demonstration of anti-motor endplate antibody and anti-muscle membrane antibody using membrane immunofluorescence technique.
Arimori S; Tada S; Nakata Y; Kobashi H; Ichikawa Y
Acta Med Okayama; 1975 Dec; 29(6):397-404. PubMed ID: 132840
[TBL] [Abstract][Full Text] [Related]
31. End-plate voltage-gated sodium channels are lost in clinical and experimental myasthenia gravis.
Ruff RL; Lennon VA
Ann Neurol; 1998 Mar; 43(3):370-9. PubMed ID: 9506554
[TBL] [Abstract][Full Text] [Related]
32. Myasthenia gravis without acetylcholine-receptor antibody: a distinct disease entity.
Mossman S; Vincent A; Newsom-Davis J
Lancet; 1986 Jan; 1(8473):116-9. PubMed ID: 2417076
[TBL] [Abstract][Full Text] [Related]
33. Increased gene expression of acetylcholine receptor and myogenic factors in passively transferred experimental autoimmune myasthenia gravis.
Asher O; Kues WA; Witzemann V; Tzartos SJ; Fuchs S; Souroujon MC
J Immunol; 1993 Dec; 151(11):6442-50. PubMed ID: 8245477
[TBL] [Abstract][Full Text] [Related]
34. Role of the main immunogenic region of acetylcholine receptor in myasthenia gravis. An Fab monoclonal antibody protects against antigenic modulation by human sera.
Tzartos SJ; Sophianos D; Efthimiadis A
J Immunol; 1985 Apr; 134(4):2343-9. PubMed ID: 3973387
[TBL] [Abstract][Full Text] [Related]
35. Seronegative myasthenia gravis.
Vincent A; McConville J; Farrugia ME; Newsom-Davis J
Semin Neurol; 2004 Mar; 24(1):125-33. PubMed ID: 15229799
[TBL] [Abstract][Full Text] [Related]
36. Prevention of experimental autoimmune myasthenia gravis by a monoclonal antibody to a complementary peptide for the main immunogenic region of the acetylcholine receptors.
Araga S; Galin FS; Kishimoto M; Adachi A; Blalock JB
J Immunol; 1996 Jul; 157(1):386-92. PubMed ID: 8683141
[TBL] [Abstract][Full Text] [Related]
37. Passive transfer of the Lambert-Eaton myasthenic syndrome: neuromuscular transmission in mice injected with plasma.
Kim YI
Muscle Nerve; 1985 Feb; 8(2):162-72. PubMed ID: 2997605
[TBL] [Abstract][Full Text] [Related]
38. Experimental myasthenia: lack of correlation between the autoantibody titer and the reduction of acetylcholine-controlled ionic channels measured at functioning endplates.
Hohlfeld R; Sterz R; Kalies I; Wekerle H; Peper K
Muscle Nerve; 1983 Feb; 6(2):160-3. PubMed ID: 6304508
[No Abstract] [Full Text] [Related]
39. Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis.
Kaminski HJ; Li Z; Richmonds C; Lin F; Medof ME
Exp Neurol; 2004 Oct; 189(2):333-42. PubMed ID: 15380483
[TBL] [Abstract][Full Text] [Related]
40. Experimental autoimmune myasthenia gravis: can pretreatment with 125I-labeled receptor prevent functional damage at the neuromuscular junction?
Sterz RK; Biro G; Rajki K; Filipp G; Peper K
J Immunol; 1985 Feb; 134(2):841-6. PubMed ID: 2578165
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
